News from AHA 2024: BROOKLYN, obicetrapib, CETPi in HeFH

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Heart Matters
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
- Subodh Verma, MD, PhD
Tirzepatide reduces HF events in patients with HFpEF and obesity
Tirzepatide reduces HF events in patients with HFpEF and obesity
Heart Matters
Tirzepatide reduces HF events in patients with HFpEF and obesity
- Milton Packer, MD
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
Heart Matters
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
- Shawna Nesbitt, MD
Effect of decision support system on early optimization of lipid-lowering therapy
Effect of decision support system on early optimization of lipid-lowering therapy
Heart Matters
Effect of decision support system on early optimization of lipid-lowering therapy
- Kausik Ray, MBChB, MD, MPhil

Obicetrapib lowers LDL-c on top of other lipid lowering therapies in HeFH